4//SEC Filing
BENDHEIM JACK 4
Accession 0001104659-25-118545
CIK 0001069899other
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 6:34 PM ET
Size
16.6 KB
Accession
0001104659-25-118545
Insider Transaction Report
Form 4
BENDHEIM JACK
DirectorPresident and CEO10% Owner
Transactions
- Conversion
Class A Common Stock
2025-12-03+30,000→ 56,800 total(indirect: See) - Sale
Class A Common Stock
2025-12-03$40.77/sh−3,520$143,511→ 53,280 total(indirect: See) - Sale
Class A Common Stock
2025-12-04$41.16/sh−3,152$129,731→ 50,128 total(indirect: See) - Sale
Class A Common Stock
2025-12-04$41.75/sh−368$15,365→ 49,760 total(indirect: See) - Conversion
Class B Common Stock
2025-12-03−30,000→ 19,961,034 total(indirect: See)Exercise: $0.00→ Class A Common Stock (30,000 underlying)
Holdings
- 16,840
Class A Common Stock
BFI Co., LLC
10% Owner
Transactions
- Conversion
Class A Common Stock
2025-12-03+30,000→ 56,800 total(indirect: See) - Sale
Class A Common Stock
2025-12-03$40.77/sh−3,520$143,511→ 53,280 total(indirect: See) - Sale
Class A Common Stock
2025-12-04$41.16/sh−3,152$129,731→ 50,128 total(indirect: See) - Sale
Class A Common Stock
2025-12-04$41.75/sh−368$15,365→ 49,760 total(indirect: See) - Conversion
Class B Common Stock
2025-12-03−30,000→ 19,961,034 total(indirect: See)Exercise: $0.00→ Class A Common Stock (30,000 underlying)
Holdings
- 16,840
Class A Common Stock
Footnotes (7)
- [F1]Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.
- [F2]The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F3]The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.30 to $41.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.72.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.73 to $41.775.
- [F7]The reported securities are directly held by Jack Bendheim.
Documents
Issuer
PHIBRO ANIMAL HEALTH CORP
CIK 0001069899
Entity typeother
Related Parties
1- filerCIK 0001241560
Filing Metadata
- Form type
- 4
- Filed
- Dec 3, 7:00 PM ET
- Accepted
- Dec 4, 6:34 PM ET
- Size
- 16.6 KB